Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
| Huvudupphovsmän: | , , , , , , , , , , , , |
|---|---|
| Materialtyp: | Conference item |
| Publicerad: |
BMJ Publishing Group Limited
2018
|
| _version_ | 1826266654262165504 |
|---|---|
| author | Nash, P Coates, L Kivitz, A Mease, P Gladman, D Covarrubias-Cobos, J Fleishaker, D Wang, C Kudlacz, E Menon, S Fallon, L Hendrikx, T Kanik, K |
| author_facet | Nash, P Coates, L Kivitz, A Mease, P Gladman, D Covarrubias-Cobos, J Fleishaker, D Wang, C Kudlacz, E Menon, S Fallon, L Hendrikx, T Kanik, K |
| author_sort | Nash, P |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T20:42:13Z |
| format | Conference item |
| id | oxford-uuid:34a929e9-eee5-4bfc-ab8d-f37def274b76 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T20:42:13Z |
| publishDate | 2018 |
| publisher | BMJ Publishing Group Limited |
| record_format | dspace |
| spelling | oxford-uuid:34a929e9-eee5-4bfc-ab8d-f37def274b762022-03-26T13:27:22ZSafety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension studyConference itemhttp://purl.org/coar/resource_type/c_c94fuuid:34a929e9-eee5-4bfc-ab8d-f37def274b76Symplectic Elements at OxfordBMJ Publishing Group Limited2018Nash, PCoates, LKivitz, AMease, PGladman, DCovarrubias-Cobos, JFleishaker, DWang, CKudlacz, EMenon, SFallon, LHendrikx, TKanik, K |
| spellingShingle | Nash, P Coates, L Kivitz, A Mease, P Gladman, D Covarrubias-Cobos, J Fleishaker, D Wang, C Kudlacz, E Menon, S Fallon, L Hendrikx, T Kanik, K Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study |
| title | Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study |
| title_full | Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study |
| title_fullStr | Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study |
| title_full_unstemmed | Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study |
| title_short | Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study |
| title_sort | safety and efficacy of tofacitinib an oral janus kinase inhibitor up to 36 months in patients with active psoriatic arthritis data from the third interim analysis of opal balance an open label long term extension study |
| work_keys_str_mv | AT nashp safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT coatesl safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT kivitza safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT measep safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT gladmand safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT covarrubiascobosj safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT fleishakerd safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT wangc safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT kudlacze safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT menons safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT fallonl safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT hendrikxt safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy AT kanikk safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy |